ancient wisdom Β· Remedy
Compound Ku Shen Injection
Compound Ku Shen Injection. Chinese patent medicines. For: Blood disease
π Names
Pinyin Name
Fu Fang Ku Shen Zhu She Ye
δΈζε (Chinese)
ε€ζΉθ¦ε注ε°ζΆ²
English Name
Compound Ku Shen Injection
π Form & Use
Category
Chinese patent medicines
Dosage Form
注ε°ε (Injection)
Administration
Injection
Source / εΊε€
ETCM
π©Ί Syndromes & Indications
Indications (δΈζ)
θ‘θ―
Indications (English)
Blood disease
2
Clinical Trials
18
Meta-Analyses
7
PubMed References
Top Conditions Studied with Compound Ku Shen Injection
Liver cancer (mostly hepatocellular carcinoma, HCC) is one o 1
Radiation-induced Oral Mucositis 1
It was estimated that lung cancer is the most common cancer 1
Advanced Colorectal Carcinoma 1
In recent years, a large number of studies have shown that c 1
In China, the compound Kushen injection has been used as adj 1
To systematically evaluate the efficacy and safety of Compou 1
Esophageal cancer (ESCA) is one of the most common cancer wo 1
The patient must be approved by pathological examination, cy 1
Compound kushen injection combined chemotherapy for stomach 1
Non-Hodgkin lymphoma (NHL) is the most common lymphoid malig 1
Colorectal cancer (CRC) is the third most common cancer and 1
π Sample Trials
NCT04204382
Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer
Unknown Β· Phase 4 Β· Radiation-induced Oral Mucositis
NCT05894694
Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer
Recruiting Β· Phase 4 Β· Advanced Colorectal Carcinoma
π Sample Meta-Analyses
CRD42021253982
Network meta-analysis of four kinds of traditional Chinese medicine injection combined with chemotherapy in the treatment of malignant ascites
1.We will search articles in three electronic database including PubMed, EMBASE,
CRD42023400730
Evidence assessment for clinical efficacy and safety of Chinese herbal injections in treating advanced nonβsmall-cell lung carcinoma: A systematic review and meta-analysis of randomized controlled trials
It was estimated that lung cancer is the most common cancer and there were 17610
CRD42016049460
The efficacy of compound Kushen injection in preventing and treating radiation-induced oral mucositis: a systematic review and meta-analysis
The patient must be approved by pathological examination, cytology or radiologic
CRD42017073181
Could a Kushen injection combined with transarterial chemoembolization (TACE) improve therapeutic efficacy and safety ofΒ advancedΒ hepatocellular carcinoma (HCC): a systematic review and network meta-analysis
Liver cancer (mostly hepatocellular carcinoma, HCC) is one of the most common ca
CRD42019133770
Compound kushen injection for stomach cancer: a systematic review and meta-analysis
Compound kushen injection combined chemotherapy for stomach cancer.
CRD42019134892
Compound kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: a meta-analysis of 37 RCTs following the PRISMA guidelines
Lung cancer remains the most common cancer and the primary cause of cancer death
π Sample References
PMID 30454068
Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway
J Exp Clin Cancer Res Β· 2018
PMID 32179631
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
J Immunother Cancer Β· 2020
PMID 32534358
A UPLC-Q-TOF/MS-based plasma metabolomics approach reveals the mechanism of Compound Kushen Injection-based intervention against non-small cell lung cancer in Lewis tumor-bearing mice
Phytomedicine Β· 2020
PMID 34646828
An Advanced Systems Pharmacology Strategy Reveals AKR1B1, MMP2, PTGER3 as Key Genes in the Competing Endogenous RNA Network of Compound Kushen Injection Treating Gastric Carcinoma by Integrated Bioinformatics and Experimental Verification
Front Cell Dev Biol Β· 2021
PMID 34649212
Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating Ξ²-catenin/c-Myc signaling
Phytomedicine Β· 2021
PMID 36016606
Exploring the pharmacological mechanism of compound kushen injection in the treatment of breast cancer using in vitro experiments: Coupling network pharmacology with GEO database
Front Oncol Β· 2022
π₯ Indications β click any to find related diseases